Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363756 | 1.00 | PDK2 (0.37) | PDK2TSHRALDH1A1ERN1NPC1 | |
| SCHEMBL24602620 | 0.80 | TSHR (0.47) | TSHRALDH1A1HPGD | |
| SCHEMBL12849942 | 0.80 | TSHR (0.47) | PDK2TSHRALDH1A1ERN1HPGD | |
| SCHEMBL29948146 | 0.79 | AKR1B1 (0.36) | PDK2TSHRERN1NPC1RAB9A | |
| SCHEMBL22165559 | 0.79 | TSHR (0.35) | PDK2TSHRERN1NPC1RAB9A | |
| SCHEMBL29429741 | 0.79 | TSHR (0.35) | PDK2TSHRERN1NPC1RAB9A | |
| SCHEMBL29428923 | 0.79 | MAPT (0.37) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM1A | |
| SCHEMBL31619139 | 0.79 | CYP3A4 (0.38) | TSHRALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20303393 | 0.79 | MAPT (0.37) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM1A | |
| SCHEMBL3208926 | 0.79 | CYP3A4 (0.38) | TSHRALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611700-B | Preparation method of 1-bromo-2, 5-dichloro-3-fluorobenzene | 辽宁东大光明化工科技有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117430481-B | Preparation method of 1-bromo-2, 5-dichloro-3-fluorobenzene | 辽宁东大光明化工科技有限责任公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117430481-A | Preparation method of 1-bromo-2, 5-dichloro-3-fluorobenzene | 辽宁东大光明化工科技有限责任公司 | 2024-01-23 | — | — | CN | claimed |
| CN-115611700-A | Preparation method of 1-bromo-2,5-dichloro-3-fluorobenzene | 辽宁东大光明化工科技有限责任公司 | 2023-01-17 | — | — | CN | claimed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007678-A1 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250289824-A1 | EGFR INHIBITOR FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2007052123-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | PDK2 4668/4885TSHR 1735/4885ALDH1A1 428/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | PDK2 1967/4885TSHR 2271/4885ALDH1A1 2283/4885 |
| US-20260007678-A1 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | PDK2 3854/4885TSHR 108/4885ALDH1A1 3340/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | PDK2 1967/4885TSHR 2271/4885ALDH1A1 2283/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | PDK2 4452/4885TSHR 945/4885ALDH1A1 2446/4885 |
| US-20250289824-A1 | EGFR INHIBITOR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | PDK2 3599/4885TSHR 1160/4885ALDH1A1 3253/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | PDK2 1398/4885TSHR 217/4885ALDH1A1 4090/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | PDK2 4422/4885TSHR 1773/4885ALDH1A1 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.